Enhancing Nursing Students' Empathy and Learning in Parkinson's Disease Through High-Fidelity Simulation and Blended Learning
Trial
N/A
Completed
March 30, 2026
High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease
Trial
N/A
Recruiting
March 30, 2026
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
Trial
Phase 2
Recruiting
March 30, 2026
Upper Extremity Rehabilitation With Virtual Reality in Parkinson's Disease Patients
Trial
N/A
Completed
March 30, 2026
Exercise Management in Parkinson's Disease
Trial
N/A
Recruiting
March 30, 2026
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
Trial
Phase 1
Active, not recruiting
March 30, 2026
Blood Flow Restriction for Optimizing Balance in Parkinson's Disease
Trial
N/A
Recruiting
March 30, 2026
Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease
Trial
Phase 2
Recruiting
March 30, 2026
Dual Frequency Stimulation in Parkinson's Disease
Trial
N/A
Recruiting
March 30, 2026
The Importance of Raising Awareness
News
Brian Grant Foundation
March 30, 2026
Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology
Trial
N/A
Recruiting
March 29, 2026
Clinical Efficacy of a telerehabilItation Protocol, for the Improvement of Balance in Degenerative Neurological Diseases
Trial
N/A
Active, not recruiting
March 29, 2026
Electrophysiology-based DBS Programming for PD
Trial
N/A
Recruiting
March 29, 2026
Neurosurgical Outcome Network
Trial
N/A
Recruiting
March 29, 2026
Effects of an Independent Walking Program With Walking Poles in People With Parkinson Disease
Trial
N/A
Terminated
March 29, 2026
Orthostatic hypotension in Parkinson disease.
Research
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
March 29, 2026
Decode the Ubiquitinome in Parkinson's Disease: From Pathological Aggregates to Targeted DUB Therapeutics.
Research
Neuroscience bulletin
March 28, 2026
Autoimmune diseases are associated with increased neurodegenerative and cerebrovascular risk, while systemic corticosteroid exposure shows limited neurodegenerative and modest vascular associations.
Research
IBRO neuroscience reports
March 28, 2026